Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study-Reference-Cited by-同舟云学术

Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study

Published:2017-07-05 Issue:2 Volume:66 Page:324-334
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Stiede Kathryn¹,Miao Wenyan¹,Blanchette Heather S.¹,Beysen Carine²,Harriman Geraldine¹,Harwood H. James¹,Kelley Heather¹,Kapeller Rosana¹,Schmalbach Tess¹,Westlin William F.¹^ORCID

Affiliation:

1. Nimbus Therapeutics; Cambridge MA

2. Kinemed; Emeryville CA

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.29246/fullpdf

Reference28 articles.

1. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging;Dyson;Frontline Gastroenterol,2014

2. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition;Harwood;Expert Opin Ther Targets,2005

3. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites;Neuschwander-Tetri;Hepatology,2010

4. Acetyl-CoA carboxylases: versatile targets for drug discovery;Tong;J Cell Biochem,2006

5. Regulation of mammalian acetyl-coenzyme A carboxylase;Kim;Annu Rev Nutr,1997

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonalcoholic fatty liver disease is a risk factor for cardiovascular disease;SCIENTIA SINICA Vitae;2024-09-01

2. Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non‐Japanese Participants;The Journal of Clinical Pharmacology;2024-08-30

3. Some paradoxes and unresolved aspects of hepatic de novo lipogenesis;npj Metabolic Health and Disease;2024-08-02

4. Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease;Journal of Clinical and Translational Hepatology;2024-07-31

5. LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases;The Journal of Clinical Endocrinology & Metabolism;2024-04-18